ProPhase Labs, Inc. (PRPH) |
| 0.1 -0.01 (-9.09%) 04-17 16:00 |
| Open: | 0.121 |
| High: | 0.135 |
| Low: | 0.08 |
| Volume: | 157,219 |
| Market Cap: | 0(M) |
| PE Ratio: | -0.01 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 0.18 |
| Resistance 1: | 0.14 |
| Pivot price: | 0.10 |
| Support 1: | 0.07 |
| Support 2: | 0.06 |
| 52w High: | 6.7 |
| 52w Low: | 0.07 |
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
| EPS | -19.800 |
| Book Value | 1.650 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.208 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -539.52 |
| Return on Assets (ttm) | -23.5 |
| Return on Equity (ttm) | -220.3 |
Wed, 15 Apr 2026
ProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections Platform - The Manila Times
Wed, 15 Apr 2026
ProPhase Labs Reports Year-End 2025 Results, Highlights - GlobeNewswire
Wed, 15 Apr 2026
$201M in medical claims could start generating cash for ProPhase in Q3 - Stock Titan
Tue, 17 Mar 2026
Biotech seeks insurer recoveries from 250+ payors for receivables-backed cash - Stock Titan
Tue, 03 Feb 2026
ProPhase Labs Initiates Potential Sale or Strategic - GlobeNewswire
Tue, 06 Jan 2026
PRPH Stock Price and Chart — OTC:PRPH - TradingView — Track All Markets
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |